Terumo (OTCMKTS:TRUMY) Stock Price Crosses Above 50-Day Moving Average Following Weak Earnings

Terumo Corp. (OTCMKTS:TRUMY)’s share price crossed above its 50 day moving average during trading on Friday following a stronger than expected earnings report. The stock has a 50 day moving average of $14.80 and traded as high as $15.08. Terumo shares last traded at $15.05, with a volume of 462,979 shares.

The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). Terumo had a return on equity of 7.03% and a net margin of 9.31%. The company had revenue of $1.96 billion for the quarter, compared to analyst estimates of $1.94 billion.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on TRUMY shares. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Nomura raised shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating. According to MarketBeat, Terumo presently has a consensus rating of “Strong Buy”.

Terumo Stock Performance

The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market cap of $22.20 billion, a price-to-earnings ratio of 31.35 and a beta of 0.82. The firm’s fifty day moving average price is $14.80 and its 200-day moving average price is $14.09.

About Terumo

Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.